FELIX study results reveal obe-cel's potential in relapsed B-cell ALL, achieving 77% remission with low severe toxicity, enhancing CAR T-cell therapy outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback